Eli Lilly excels in capital allocation
Eli Lilly is leveraging massive GLP-1 cash flows to execute smart bolt-on acquisitions and build a long-term post-patent portfolio.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.